Related Experiment Videos
Evaluation of prajmalium-induced cholestasis by immunologic tests
Archives of Internal Medicine
|December 1, 1981
Summary
Prajmalium bitartrate can cause cholestatic jaundice due to idiosyncratic reactions. Immunologic processes, including specific antibodies and positive assays, appear to play a role in this drug-induced liver injury.
Area of Science:
- Hepatology
- Clinical Immunology
- Pharmacology
Background:
- Drug-induced liver injury (DILI) is a significant clinical concern.
- Cholestatic jaundice is a severe form of DILI.
- Prajmalium bitartrate is a medication with potential hepatotoxic effects.
Observation:
- Four patients developed cholestatic jaundice after prajmalium bitartrate administration.
- Clinical and morphologic features suggested an idiosyncratic drug reaction.
- Histologic, ultrastructural, and immunologic assessments were performed.
Findings:
- Two antibodies with a granular pattern along bile canaliculi were detected in all patients via immunofluorescence.
- Autoimmune markers were present in one patient's serum.
- Migration-inhibition factor assay was positive in two patients, indicating a drug-specific immune response.
Implications:
- The findings suggest that immunologic mechanisms contribute to prajmalium bitartrate-induced cholestatic jaundice.
- This highlights the potential role of immune-mediated idiosyncratic reactions in DILI.
- Further research into drug-specific immune responses in hepatotoxicity is warranted.